M
Matthias Miederer
Researcher at University of Mainz
Publications - 91
Citations - 3212
Matthias Miederer is an academic researcher from University of Mainz. The author has contributed to research in topics: Medicine & In vivo. The author has an hindex of 21, co-authored 76 publications receiving 2404 citations. Previous affiliations of Matthias Miederer include Technische Universität München & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Tumor Therapy with Targeted Atomic Nanogenerators
Michael R. McDevitt,Dangshe Ma,Lawrence T. Lai,Jim Simon,Paul E. Borchardt,R. Keith Frank,Karen Y. Wu,Virginia Pellegrini,Michael Curcio,Matthias Miederer,Neil H. Bander,David A. Scheinberg +11 more
TL;DR: Methods to target molecular-sized generators of alpha-emitting isotope cascades to the inside of cancer cells using actinium-225 coupled to internalizing monoclonal antibodies killed leukemia, lymphoma, breast, ovarian, neuroblastoma, and prostate cancer cells at becquerel (picocurie) levels.
Journal ArticleDOI
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.
Ugur Sahin,Petra Oehm,Evelyna Derhovanessian,Robert A. Jabulowsky,Mathias Vormehr,Maike Gold,Daniel Maurus,Doreen Schwarck-Kokarakis,Andreas Kuhn,Tana Omokoko,Lena M. Kranz,Mustafa Diken,Sebastian Kreiter,Heinrich Haas,Sebastian Attig,Richard Rae,Katarina Cuk,Alexandra Kemmer-Brück,Andrea Breitkreuz,Claudia Tolliver,Janina Caspar,Juliane Quinkhardt,Lisa Hebich,Malte Stein,Alexander Hohberger,Isabel Vogler,Inga Liebig,Stephanie Renken,Julian Sikorski,Melanie Leierer,Verena Müller,Heidrun Mitzel-Rink,Matthias Miederer,Christoph Huber,Stephan Grabbe,Jochen Utikal,Andreas Pinter,Roland Kaufmann,Jessica C. Hassel,Carmen Loquai,Özlem Türeci +40 more
TL;DR: Results of an exploratory interim analysis from a phase I trial show that an RNA vaccine targeted towards four melanoma-associated antigens produces durable objective responses in patients with melanoma that are accompanied by strong CD4 + and CD8 + T-cell immunity.
Journal ArticleDOI
Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications ☆
TL;DR: This article reviews the literature pertaining to the research, development, and utilization of targeted 225 Ac to potently and specifically affect cancer.
Journal ArticleDOI
Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy.
Kathrin Renner,Christina Bruss,Annette Schnell,Gudrun E. Koehl,Holger M. Becker,Matthias Fante,Ayse Nur Menevse,Nathalie Kauer,Raquel Blazquez,Lisa Hacker,Sonja Maria Decking,Toszka Bohn,Stephanie Faerber,Katja Evert,Lisa Aigle,Sabine Amslinger,Maria Landa,Oscar Krijgsman,Elisa A. Rozeman,Christina Brummer,Peter J. Siska,Katrin Singer,Stefanie Pektor,Matthias Miederer,Katrin Peter,Eva Gottfried,Wolfgang Herr,Ibtisam Marchiq,Jacques Pouysségur,William R. Roush,SuFey Ong,Sarah Warren,Tobias Pukrop,Philipp Beckhove,Sven A. Lang,Tobias Bopp,Christian U. Blank,John L. Cleveland,Peter J. Oefner,Katja Dettmer,Mark J. Selby,Marina Kreutz +41 more
TL;DR: It is reported that melanoma patients with high expression of glycolysis-related genes show a worse progression free survival upon anti-PD1 treatment, and this findings support the rationale for targeting Glycolytic tumors together with checkpoint inhibitors in clinical trials.
Journal Article
Targeted actinium-225 in vivo generators for therapy of ovarian cancer.
TL;DR: In conclusion, i.p. administration with a (225)Ac-labeled internalizing anti-HER-2/neu antibody can extend survival significantly in a nude mouse model of human ovarian cancer at levels that produce no apparent gross toxicity.